# Allegro Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/allegro-diagnostics

- Industry: Biotechnology
- Headquarters: Maynard, US
- Website: www.allegrodx.com
- Total disclosed funding: $9.4M
- Latest round: Series A (Jun 30, 2011)
- Investors on record: 3

## About

Allegro Diagnostics specializes in advanced diagnostic solutions, providing innovative testing products and services for the healthcare sector, particularly in oncology and infectious diseases.Allegro Diagnostics, founded in 2006 and headquartered in Maynard, US, focuses on developing advanced diagnostic tools. The company has undergone significant changes, including its acquisition by Veracyte Inc. in September 2014 for USD 21 mn. Allegro Diagnostics has participated in 4 deals in total, with its most recent deal occurring on September 4, 2014. The founder's background is not publicly detailed, and there are no known subsidiaries or parent companies associated with Allegro Diagnostics.AllegroDX specializes in advanced diagnostic solutions, focusing on providing innovative testing products and services for the healthcare sector. Their core offerings include a range of proprietary assays and testing platforms designed to aid in the early detection and monitoring of various medical conditions. These products aim to address critical needs in patient care, particularly in the fields of oncology, infectious diseases, and chronic conditions, facilitating timely and accurate diagnoses. AllegroDX serves a diverse client base, including hospitals, clinical laboratories, and healthcare providers primarily in North America and select markets in Europe and Asia. By delivering high-quality diagnostic tools, they help healthcare professionals make informed decisions in patient management and treatment strategies.AllegroDX generates revenue through a subscription-based model for its diagnostic testing services, complemented by B2B sales to healthcare institutions. Their revenue structure includes direct transactions with hospitals and laboratories that utilize their testing platforms and assays in patient care settings. Typically, clients engage in partnerships that allow for bulk purchasing of their flagship diagnostic products, ensuring reliable access to essential testing resources. Pricing plans are structured around individual tests and service packages tailored to meet the specific needs of healthcare providers, facilitating streamlined operations in clinical environments. This transactional model underscores AllegroDX’s commitment to providing value through innovative diagnostic solutions that enhance clinical outcomes for patients.Allegro Diagnostics is focused on expanding its product offerings and geographic reach. The company is in the process of developing new diagnostic products aimed at improving detection capabilities in oncology and infectious diseases. Future plans include targeting expansion into new markets across Europe and Asia by 2025. The recent funding from Veracyte Inc. will be utilized to support these product developments and to enhance market penetration efforts.

## Funding rounds

- Series A, Jun 30, 2011, $5.4M — Kodiak Venture Partners, Catalyst Health Ventures
- Series A, Mar 7, 2008, $4M — Kodiak Venture Partners, Catalyst Health Ventures, Boston University Community Technology Fund

## Investors

- Kodiak Venture Partners (https://capitalatlas.ai/funds/kodiak-venture-partners) — Series A
- Catalyst Health Ventures (https://capitalatlas.ai/funds/catalyst-health-ventures) — Series A
- Boston University Community Technology Fund — Series A